Sunitinib and Hypothyroidism in Cancer Patients
Author Information
Author(s): Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P
Primary Institution: University Hospital Gasthuisberg, Catholic University Leuven
Hypothesis
What is the incidence and severity of hypothyroidism in patients receiving sunitinib for cancer treatment?
Conclusion
Sunitinib can induce (sub-)clinical hypothyroidism, necessitating close monitoring of thyroid function.
Supporting Evidence
- 16 patients (27%) developed sub- or clinical hypothyroidism requiring hormone replacement.
- 20 patients (34%) showed at least one elevated TSH not requiring treatment.
- 34% of patients did not develop any biochemical thyroid abnormality.
Takeaway
Some cancer patients taking a medicine called sunitinib can get a problem with their thyroid, which helps control energy and growth. Doctors need to check their thyroid levels regularly.
Methodology
A prospective observational study assessing thyroid function in patients treated with sunitinib for metastatic renal cell carcinoma or gastrointestinal stromal tumors.
Potential Biases
Potential bias due to the single-center design and the exclusion of patients with prior thyroid issues.
Limitations
The study was limited by the exclusion of patients with pre-existing thyroid conditions and the variability in definitions of hypothyroidism in previous studies.
Participant Demographics
Median age was 61 years, with a male to female ratio of 3:1.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website